November 17, 2022 — Neuraptive Therapeutics, Inc. Announces Appointment of Leading Industry Executive, Dr. Robert R. Ruffolo as New Director to the Board. Read more.
October 24, 2022 — Neuraptive Therapeutics Announces Key Organizational Updates to Support the Company’s Advancements in Nerve Repair. Read more.
July 21, 2022 — Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma. Read more.
April 13, 2021 — Neuraptive Therapeutics Announces FDA Clearance of a Second IND Application for NTX-001 in the Prevention of Postoperative Facial Paralysis and Plans to Initiate a Phase 2 Clinical Study Later This Year. Read more.
October 20, 2020 — Neuraptive Therapeutics Announces Activation of First Clinical Site in Phase 2 Study of NTX-001 for the Treatment of Nerve Repair and the Appointment of Industry Veteran David Pierce to Board of Directors. Read more.
June 23, 2020 — Neuraptive Therapeutics Appoints Robert S. Radie as Chief Executive Officer and Chairman of the Board. Read more.
May 14, 2020 — Neuraptive Therapeutics Announces FDA has Granted Fast Track Designation to NTX-001 Clinical Development Program for Treatment of Patients with Peripheral Nerve Injuries. Read more.
April 28, 2020 — Neuraptive Therapeutics Announces FDA Clearance of IND Application for NTX-001, a Novel Approach for the Treatment of Patients with Peripheral Nerve Injuries. Read more.
June 11, 2019 — Neuraptive Therapeutics Announces Evan Tzanis as Executive Vice President, Head of R&D. Read more.
December 19, 2018Neuraptive Therapeutics, Inc., a biotech startup based in Colorado and Pennsylvania, raised $11.5 million in a Series A funding round led by New Rhein Healthcare Investors LLC. — Read more.